The intent of the proposed research is to follow prospectively all available SCID infants born in the United States and Canada to evaluate systematically for the first time factors influencing the outcomes of the multiple forms of hematopoietic cell therapy (HCT) for SCID currently being employed. This study will use state of the art methods to define the molecular genotypes and characterize serially multiple key parameters of immunological reconstitution.
Aim 1) To determine the effects patient-related factors have on survival, time course of immune reconstitution and clinical outcome of HCT for SCID, including age at transplantation, presence of viral infections, lymphocyte phenotype, molecular genotype and the presence of transplacentally transferred maternal lymphocytes.
Aim 2) To determine the effects adequacy of HLA matching of donor and recipient have on survival, the time course of immune reconstitution and clinical outcome of HCT for SCID. For the majority of patients who must receive HLA-mismatched transplants, source of donor cells (haploidentical mother vs. father, HLA-matched unrelated adult or cord blood), methods of T cell depletion or CD34 cell selection, and cell numbers given (both CD34+ stem cells and CD3+ T cells) will be comparatively examined, with particular focus on the occurrence, severity and duration of GVHD and ultimate multilineage engraftment.
Aim 3) To determine the effects the use (or not) and type of pre-transplant conditioning have on survival and on the immunologic and clinical outcomes of HCT. This project will help accomplish the proposal's overall objective of improving definitive therapy for SCID by comparing relatively short term outcomes of the different treatments currently being employed for HCT in SCID in a temporally homogeneous cohort of patients under defined patient and donor circumstances. It will define early biomarkers that predict survival, the earliest immune reconstitution or lack of it, and the risk for chronic GVHD and/or autoimmune disease. It can be anticipated that the results of this prospective study will help design clinical trials aiming at defining strategies to optimize survival, long-term immune reconstitution and to reduce complications after HCT for SCID.
Primary immune deficiencies (PIDs) are rare, life-threatening inherited defects in the immune system. This prospective study of children with severe combined immunodeficiency (SCID) will help accomplish the Primary Immune Deficiency Treatment Consortium (PIDTC)'s overall objective of identifying pre-HCT and early post HCT biologic factors that best predict successful engraftment, immune reconstitution, and outcome with minimal toxicity.
|Long-Boyle, Janel R; Savic, Rada; Yan, Shirley et al. (2015) Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit 37:236-45|
|Haddad, Elie; Allakhverdi, Zoulfia; Griffith, Linda M et al. (2014) Survey on retransplantation criteria for patients with severe combined immunodeficiency. J Allergy Clin Immunol 133:597-9|
|Shearer, William T; Dunn, Elizabeth; Notarangelo, Luigi D et al. (2014) Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 133:1092-8|
|Dvorak, Christopher C; Hassan, Amel; Slatter, Mary A et al. (2014) Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol 134:935-943.e15|
|Lee, Yu Nee; Frugoni, Francesco; Dobbs, Kerry et al. (2014) A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol 133:1099-108|
|Pai, Sung-Yun; Cowan, Morton J (2014) Stem cell transplantation for primary immunodeficiency diseases: the North American experience. Curr Opin Allergy Clin Immunol 14:521-6|
|Griffith, Linda M; Cowan, Morton J; Notarangelo, Luigi D et al. (2014) Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 133:335-47|
|Medical Advisory Committee of the Immune Deficiency Foundation; Shearer, William T; Fleisher, Thomas A et al. (2014) Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 133:961-6|
|Chinen, Javier; Notarangelo, Luigi D; Shearer, William T (2014) Advances in basic and clinical immunology in 2013. J Allergy Clin Immunol 133:967-76|
|Pai, Sung-Yun; Logan, Brent R; Griffith, Linda M et al. (2014) Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 371:434-46|
Showing the most recent 10 out of 33 publications